- Login
- Register & Subscribe
- Language: EN FR DE
Company News
GSK pays $23 million upfront for rights to fusion-protein technology
Thursday 5 August 2010
GlaxoSmithKline Plc has agreed to pay $23 million upfront for exclusive access to technology developed by Amplimmune Inc of the US for potential therapies for cancer and other diseases. Specifically, GSK will obtain rights to a molecule targeting the membrane protein, PD-1.
Location
United Kingdom
See map: Google Maps
Shire sets higher spending targets
Wednesday 4 August 2010
Shire Plc expects to increase its spending on research and development this year, even as it prepares to commit €428 million to complete its latest acquisition- an all-cash offer for Movetis NV of Belgium.
Location
Ireland
Wilex completes rights issue
Wednesday 4 August 2010
Wilex AG has announced the successful completion of a rights issue which has raised €10 million in new money. The proceeds will be used to finance the ongoing clinical development of the company’s oncology portfolio.
Location
Germany
See map: Google Maps
UCB confirms 2010 financial outlook
Wednesday 4 August 2010
With a debt restructuring completed and its core products booking substantial revenue gains in the first half, UCB SA has confirmed its forecast for 2010 revenue of €3 billion and a profit of €700 million.
Location
Belgium
Shire to offer €19 per share for Movetis
Tuesday 3 August 2010
Shire Plc has announced a tender offer for the recently-listed Belgian company, Movetis NV, which has a product for chronic constipation on markets in the European Union. Shire is offering €19 per share in cash for Movetis, representing a premium of 74% to Movetis’s closing price on NYSE Euronext Brussels on 2 August 2010.
Location
Ireland
First clinical trial of embryonic stem cell therapy gets go-ahead
Sunday 1 August 2010
Geron Corporation said it has received clearance from the Food and Drug Administration to proceed with a human trial of an embryonic stem cell-based therapy in patients with acute spinal cord injury.
Location
United States
See map: Google Maps
NicOx to seek post-review discussions with FDA
Friday 30 July 2010
NicOx SA will be seeking a meeting with the Food and Drug Administration to discuss the agency’s refusal to approve its lead product, naproxcinod, for marketing, the company’s chief executive, Michele Garufi, told analysts in a conference call on 30 July.
Location
France
Wilex recommends shareholders not accept dievini Hopp offer
Friday 30 July 2010
The management of Wilex AG is asking shareholders not to accept an offer for the company from dievini Hopp BioTech holding GmbH. The venture capital firm was obliged to make the offer after its stake in Wilex moved above 30%.
Location
Germany
See map: Google Maps
Generic competition puts pressure on Sanofi-Aventis
Thursday 29 July 2010
Sanofi-Aventis managed to offset the impact of generic competition for some of its major products in the quarter and half year ended June 2010. However, it changed its guidance for profit per share at constant exchange rates.
Location
France
AstraZeneca raises its earnings guidance and share buy-back target
Thursday 29 July 2010
For the second time this year, AstraZeneca Plc has raised its guidance for earnings per share in 2010 even as it anticipates a slight decline in revenue and downward pressure on prices in Europe from healthcare reforms. The Anglo-Swedish multinational also said that it is raising its target for the repurchase of its shares on the market to $2 billion, up from $1 billion, and will be paying an interim dividend of $0.70 per share.
Location
United Kingdom
See map: Google Maps
Select a News Category
Recent Appointments
Tim Edwards elected chairman of BIA
Tuesday September 7 2010
Index Ventures appoints antibody expert as partner
Friday September 3 2010
Colin Stewart appointed CEO at Amarin
Friday August 20 2010
Karl Keegan nominated as CFO of Pharming
Friday August 20 2010
Axel Müller becomes CEO at SkyePharma
Thursday August 19 2010